Wednesday, December 12, 2018 9:55:52 AM
As an investor, you should be interested in the market cap of DECN, right. As well as eventual share price. The amount of money Bozo Berman needs to distribute any product will be highly dilutive, so investments in DECN on a stock level is a joke. Without audited financials, there will be no serious investors.
Having approved FDA products is great, and that is the only thing I would give Bozo Berman good grades on, but what good is it if there are pathetic sales.
Stock investors are pretty much screwed here. Maybe if your cost is .02 you might make a few bucks, even then I doubt it.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM